{
  "docId": "019de072-75de-708e-aad9-55788df6c953",
  "docSlug": "5188528054c3088b6a98b04815eb3ce3",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 40,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Slide presents two Kaplan-Meier style survival/event curves alongside key efficacy metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-75de-708e-aad9-55788df6c953/22",
  "deckHref": "/decks/019de072-75de-708e-aad9-55788df6c953",
  "deckJsonHref": "/decks/019de072-75de-708e-aad9-55788df6c953.json",
  "deckAnchorHref": "/decks/019de072-75de-708e-aad9-55788df6c953#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.53,
        "y": 0.31
      },
      "kind": "chart",
      "text": "Evusheld vs Placebo Kaplan-Meier curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "507f9981-7527-48ac-8112-4a772fdcf804",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.44,
        "x": 0.04,
        "y": 0.31
      },
      "kind": "chart",
      "text": "Nirsevimab vs Placebo Kaplan-Meier curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "886249f2-173d-4266-b145-e2ddd46cb83f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "74.5% efficacy against medically-attended LRTI associated with RSV; 77.3% efficacy against hospitalisations from LRTI associated with RSV",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "50fb20ce-268e-4bc2-bfc6-042e2934a32b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.44,
        "x": 0.53,
        "y": 0.75
      },
      "kind": "list",
      "text": "77% risk reduction against symptomatic COVID-19 at 3 months; 83% risk reduction at >6 months",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2498d12-96a1-4062-9975-269fa0998ee2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.55,
        "x": 0.02,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "1. Hammit et al, NEJM 2022; 386:837-846. 2. Levin et al, NEJM oa2116620. LRTI = lower respiratory tract infections; RSV = respiratory syncytial virus.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8b4e6109-3b97-4cf5-8baa-e521abc41ed0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.51,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Scientific leadership in long-acting antibodies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da767907-efb8-4de0-a494-b8ece718b849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.68,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: Q1 2022 R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ce9b1d3-4475-46a2-8bc9-87ef3ceb9b6d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}